Sveriges Riksbank
22.2.2021 07:04:06 CET | Globenewswire | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS
| Auction date | 2021-02-18 |
| Loan | 196 |
| Coupon | 1.00 % |
| ISIN-code | SE0015244991 |
| Maturity | 2026-03-18 |
| Tendered volume, SEK mln | 800 +/- 400 |
| Volume offered, SEK mln | 3,200 |
| Volume bought, SEK mln | 800 |
| Number of bids | 5 |
| Number of accepted bids | 1 |
| Average yield | 0.251 % |
| Lowest accepted yield | 0.251 % |
| Highest yield | 0.251 % |
| % accepted at lowest yield | 100.00 |
| Auction date | 2021-02-18 |
| Loan | 1591 |
| Coupon | 0.50 % |
| ISIN-code | SE0013882644 |
| Maturity | 2026-06-01 |
| Tendered volume, SEK mln | 2,000 +/- 1,000 |
| Volume offered, SEK mln | 9,550 |
| Volume bought, SEK mln | 2,000 |
| Number of bids | 11 |
| Number of accepted bids | 2 |
| Average yield | 0.279 % |
| Lowest accepted yield | 0.279 % |
| Highest yield | 0.279 % |
| % accepted at lowest yield | 80.00 |
| Auction date | 2021-02-18 |
| Loan | 147 |
| Coupon | 2.00 % |
| ISIN-code | SE0009383664 |
| Maturity | 2026-06-17 |
| Tendered volume, SEK mln | 700 +/- 350 |
| Volume offered, SEK mln | 2,600 |
| Volume bought, SEK mln | 700 |
| Number of bids | 4 |
| Number of accepted bids | 2 |
| Average yield | 0.287 % |
| Lowest accepted yield | 0.287 % |
| Highest yield | 0.287 % |
| % accepted at lowest yield | 50.00 |
| Auction date | 2021-02-18 |
| Loan | 580 |
| Coupon | 1.00 % |
| ISIN-code | SE0013101722 |
| Maturity | 2025-12-17 |
| Tendered volume, SEK mln | 700 +/- 350 |
| Volume offered, SEK mln | 3,350 |
| Volume bought, SEK mln | 700 |
| Number of bids | 7 |
| Number of accepted bids | 2 |
| Average yield | 0.226 % |
| Lowest accepted yield | 0.220 % |
| Highest yield | 0.228 % |
| % accepted at lowest yield | 28.57 |
| Auction date | 2021-02-18 |
| Loan | 519 |
| Coupon | 1.50 % |
| ISIN-code | SE0012324341 |
| Maturity | 2026-09-16 |
| Tendered volume, SEK mln | 600 +/- 300 |
| Volume offered, SEK mln | 2,400 |
| Volume bought, SEK mln | 600 |
| Number of bids | 5 |
| Number of accepted bids | 1 |
| Average yield | 0.315 % |
| Lowest accepted yield | 0.315 % |
| Highest yield | 0.315 % |
| % accepted at lowest yield | 100.00 |
| Auction date | 2021-02-18 |
| Loan | 2512 |
| Coupon | 1.00 % |
| ISIN-code | SE0013877214 |
| Maturity | 2025-12-17 |
| Tendered volume, SEK mln | 200 +/- 100 |
| Volume offered, SEK mln | 600 |
| Volume bought, SEK mln | 200 |
| Number of bids | 3 |
| Number of accepted bids | 1 |
| Average yield | 0.247 % |
| Lowest accepted yield | 0.247 % |
| Highest yield | 0.247 % |
| % accepted at lowest yield | 100.00 |
| Auction date | 2021-02-18 |
| Loan | 5533 |
| Coupon | 1.25 % |
| ISIN-code | SE0010442731 |
| Maturity | 2023-09-20 |
| Tendered volume, SEK mln | 1,000 +/- 500 |
| Volume offered, SEK mln | 2,000 |
| Volume bought, SEK mln | 1,000 |
| Number of bids | 2 |
| Number of accepted bids | 1 |
| Average yield | -0.012 % |
| Lowest accepted yield | -0.012 % |
| Highest yield | -0.012 % |
| % accepted at lowest yield | 100.00 |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Newcap Holdings29.3.2026 12:19:20 CEST | Pressemeddelelse
NewCap Holding A/S har indgået en aftale, betinget af underskrivelse af endelige aftaledokumenter m.v., om erhvervelse af dansk selskab indenfor compliance og risikostyringsservices – Intern viden
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom